BMS-754807

For research use only. Not for use in humans.

製品コードS1124

BMS-754807化学構造

CAS No. 1001350-96-4

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

サイズ 価格(税別) 在庫  
JPY 31800 あり
JPY 46800 あり
JPY 129800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

IGF-1R阻害剤の選択性比較

生物活性

製品説明 BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
特性 Muti-inhibitor of the IGR-1R/IR family.
ターゲット
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
TrkB [1]
(Cell-free assay)
Met [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
1.7 nM 1.8 nM 4.1 nM 5.6 nM 7.4 nM
体外試験

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGF-Sal M2\hUmtqdmG|ZTDhd5NigQ>? MmLkbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXIhMEmFNUCgQUAyO26PKTDhcoQhfGinIHTve45{fHKnYX2geIFz\2W2czDBb5QhMEmFNUCgQUAzOm6PKTDhcoQhVUGSSzCoTWM2OCB;IEGzcm0q M1zJOlE6Pzd6MEK0
IGF-Sal MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnS1TWM2OD15IH7N M3r0cVE6Pzd6MEK0
CCRF-CEM (ALL) NHLDXZNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHXMdGF,PSEQvF2= MoXvSG1UVw>? M4TXemlEPTB;MT6yN|kh|ryP NHTTVYgyQTl7NkK3Ni=>
PC3 M2\zXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlTJglUh|ryP NYjacnFoTE2VTx?= NVHQSWVtUUN3ME2wMlk3PSEQvF2= MUmxPVk6PjJ5Mh?=
JD MnPSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Mni1glUh|ryP M4O1XWROW09? MYDJR|UxRTBwM{mxJO69VQ>? NFXyTIsyQTl7NkK3Ni=>
DU145 M4XEUmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHv2eGN,PSEQvF2= NVrORYVlTE2VTx?= NY[2SmVLUUN3ME2xMlQ3PSEQvF2= MVqxPVk6PjJ5Mh?=
KAG NV3FbZFsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEnnS|R,PSEQvF2= NIq0fXNFVVOR MlXHTWM2OD1zLk[2OUDPxE1? Ml20NVk6QTZ{N{K=
K-562 (CML) MmXWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M2e4R542KM7:TR?= M13C[mROW09? MWnJR|UxRTJwM{CyJO69VQ>? MYmxPVk6PjJ5Mh?=
B6-P210 (Murine ALL) NEX1eVBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYr+OUDPxE1? MoezSG1UVw>? NWK3NGI2UUN3ME2xMlI6OyEQvF2= M4DqZlE6QTl4Mkey
LN CAP-FGC NWToT|B5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVTpcWw6hjVizszN MoLBSG1UVw>? M1HROmlEPTB;MT60N|Qh|ryP Mm\PNVk6QTZ{N{K=
VW NHjoTm5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MlfOglUh|ryP NVnoVGNyTE2VTx?= NHL2OWdKSzVyPUCuNFE6KM7:TR?= M1fXfFE6QTl4Mkey
MV411 (B Myelomonocytic) M33hS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NUHDcpFUhjVizszN NWXLN5FDTE2VTx?= MWDJR|UxRTBwM{Og{txO NELqcmwyQTl7NkK3Ni=>
MDA-PCa-2b MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoDFglUh|ryP MlrLSG1UVw>? MmC1TWM2OD1yLkC5PEDPxE1? NXfpPGhvOTl7OU[yO|I>
LG MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NInUcVZ,PSEQvF2= NXLB[XV2TE2VTx?= NIfJXYlKSzVyPUCuNFM5KM7:TR?= NUfYfY5vOTl7OU[yO|I>
RS411 (B cell precursor-ALL) MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MonJglUh|ryP NGP0bHdFVVOR MYrJR|UxRTBwMUCyJO69VQ>? MnT0NVk6QTZ{N{K=
22-r-1 NYm3b3E1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkjNglUh|ryP NInnWY5FVVOR MVzJR|UxRTBwMUe1JO69VQ>? MUWxPVk6PjJ5Mh?=
5838 MlTxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NE\yOJF,PSEQvF2= MknySG1UVw>? MlnVTWM2OD1yLkCzOEDPxE1? NF7LflgyQTl7NkK3Ni=>
P388 (Murine) NGH1T4ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MkXGglUh|ryP M1e3N2ROW09? MYXJR|UxRTRwMkeg{txO MlfRNVk6QTZ{N{K=
A2780/S MlnuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXPQV|lohjVizszN NUXW[JJFTE2VTx?= NXvJbpNvUUN3ME2wMlEzOiEQvF2= NH:1RZgyQTl7NkK3Ni=>
RDES NXW3dFFVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mnj0glUh|ryP NEnENIdFVVOR MYXJR|UxRTBwMEGyJO69VQ>? MUmxPVk6PjJ5Mh?=
B6-T315I (Murine B-ALL) MkfGS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1r3TJ42KM7:TR?= MoPpSG1UVw>? NEXWNZRKSzVyPUKuPFMh|ryP MoO1NVk6QTZ{N{K=
TOV 112D MljnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{PXZp42KM7:TR?= NIjrT4FFVVOR M3LxdmlEPTB;Mj6xOFYh|ryP NIHUNWgyQTl7NkK3Ni=>
TC32 NH20Z|lIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWL+OUDPxE1? MXLEUXNQ NEH0WY1KSzVyPUCuNFA5KM7:TR?= NGDtNGsyQTl7NkK3Ni=>
HL60 (acute myelocytic) NIDOSVVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUnVbGQ1hjVizszN MVHEUXNQ M1L0fWlEPTB;MD6xNkDPxE1? M2rL[lE6QTl4Mkey
TOV 21G M1W5Smdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYXV[G55hjVizszN NV2yO|lHTE2VTx?= MXXJR|UxRTRwMke5JO69VQ>? MljqNVk6QTZ{N{K=
TC71 Mmm5S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MknCglUh|ryP NHfP[VZFVVOR NH;XTpJKSzVyPUCuNFE1KM7:TR?= M4\4V|E6QTl4Mkey
HPN-ALL (T-cell) MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX;+OUDPxE1? NWTie|hVTE2VTx?= NFnOd|VKSzVyPUCuOVIh|ryP NHHUd4EyQTl7NkK3Ni=>
A2780R MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVfoNoRnhjVizszN M3iyemROW09? Mn3CTWM2OD1zLkW2OEDPxE1? MV2xPVk6PjJ5Mh?=
Rh1 M4XDeGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUP+OUDPxE1? NXLmO|BOTE2VTx?= MoDnTWM2OD1yLkCyO{DPxE1? MUmxPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid) NVzOb291T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXH+OUDPxE1? NYTn[4RyTE2VTx?= NH3UXmtKSzVyPUCuNVYh|ryP NWf1W2tLOTl7OU[yO|I>
sk-ov-3 MmDPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGHYTIl,PSEQvF2= NIHB[GFFVVOR M1G2SmlEPTB;NT6xJO69VQ>? M2KxVFE6QTl4Mkey
ME M2fpZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXv+OUDPxE1? NHHlcVRFVVOR NUfDOlFLUUN3ME2wMlAyPSEQvF2= NITlTm8yQTl7NkK3Ni=>
L1210 (Murine lymphocytic) M1e5NGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{TqOp42KM7:TR?= NYrScXBUTE2VTx?= NFK3e4pKSzVyPUKuN|kh|ryP MYKxPVk6PjJ5Mh?=
sw-626 M1;0VGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NF\pT5p,PSEQvF2= NWDaUmlkTE2VTx?= NULpXZB7UUN3ME2yMlMxPiEQvF2= MV6xPVk6PjJ5Mh?=
CTR M3XUSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH\GN5l,PSEQvF2= M3e0NWROW09? M2\N[mlEPTB;MD6yOVMh|ryP MlnNNVk6QTZ{N{K=
ML2 (Myelomonocytic) MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MkP2glUh|ryP NV3jRo04TE2VTx?= MYjJR|UxRTBwMEmg{txO M3;TNFE6QTl4Mkey
ovcar-3 M1LSPGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NILWWmZ,PSEQvF2= MkP6SG1UVw>? NIjOc2JKSzVyPUWg{txO MkfLNVk6QTZ{N{K=
Rh36 NIXjWZlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NEfoWY9,PSEQvF2= M3z4bmROW09? M{nKcGlEPTB;MT60N|Ih|ryP NXXwclRHOTl7OU[yO|I>
MOLM-13 (acute myeloid) MmjjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnK1glUh|ryP M2O5b2ROW09? NVzLUWNMUUN3ME2wMlQzKM7:TR?= NEHMVZcyQTl7NkK3Ni=>
ovcar-4 NVvuboVjT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NV\IU|JChjVizszN NIm4OlNFVVOR MVHJR|UxRTFizszN Mn3pNVk6QTZ{N{K=
Rh41 MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mn3qglUh|ryP NFPtcZdFVVOR NVzzZ4N3UUN3ME2wMlAxPSEQvF2= NWSyUmdFOTl7OU[yO|I>
Mutz 2 (acute myeloid) MlnRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXXrb4t2hjVizszN NHnDb5ZFVVOR MWPJR|UxRTFwMUWg{txO MWSxPVk6PjJ5Mh?=
ovcar-5 NXzJbW9[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUD+OUDPxE1? MnTUSG1UVw>? M3PCV2lEPTB;MD6wOUDPxE1? MYqxPVk6PjJ5Mh?=
RD1 NXXHemNVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWPGVmpLhjVizszN NI\aPJJFVVOR M3Lje2lEPTB;MD6wOlgh|ryP NIjCd4syQTl7NkK3Ni=>
OCI-AML 2 (acute myeloid) MnXPS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NH7q[mF,PSEQvF2= NEfq[JNFVVOR M4fx[mlEPTB;Mz6zN{DPxE1? NEfqXoEyQTl7NkK3Ni=>
786-O NFzKdIZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH\FXZZ,PSEQvF2= NFfmcXBFVVOR M1OzUWlEPTB;MT62OFch|ryP NGXXcHQyQTl7NkK3Ni=>
A673 NUXuTHBxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVrwRW5KhjVizszN NYrpd4c4TE2VTx?= NYDxbGtqUUN3ME2wMlQxQCEQvF2= NVHpU4x2OTl7OU[yO|I>
TALL-1 (T-cell) MX;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWH+OUDPxE1? M{\WbmROW09? NFzJXmxKSzVyPUGuNlgh|ryP MXKxPVk6PjJ5Mh?=
151-B NHLrPJJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NInaZ5h,PSEQvF2= M3\xSGROW09? MVnJR|UxRTJwNkeg{txO NGfncnAyQTl7NkK3Ni=>
PFSK-1 Ml2xS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUfKWnZ[hjVizszN M{PvOWROW09? MXXJR|UxRTBwMUOyJO69VQ>? NUfpSG9uOTl7OU[yO|I>
THP-1 NXnSZ4FXT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkH5glUh|ryP MkfXSG1UVw>? Mm\WTWM2OD14LkW4JO69VQ>? Mm\YNVk6QTZ{N{K=
HEK293 MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NY\BdHZphjVizszN NInwWY5FVVOR NX\S[Xd7UUN3ME2wMlkyPSEQvF2= M2C1d|E6QTl4Mkey
DAOY NV\PTmRDT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4rzdJ42KM7:TR?= MUXEUXNQ MXHJR|UxRTFwOUe5JO69VQ>? M{LIR|E6QTl4Mkey
SET2 M1jJXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUH+OUDPxE1? MkPrSG1UVw>? MkS3TWM2OD1yLkK5PEDPxE1? M4DjRlE6QTl4Mkey
HTB-46 NF\3WJlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYL+OUDPxE1? Mn;PSG1UVw>? MmrzTWM2OD13LkK1JO69VQ>? MoHpNVk6QTZ{N{K=
SK-NAS NIDpNYpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH7wfWx,PSEQvF2= NGr0SW5FVVOR MnmzTWM2OD1yLkS5O{DPxE1? MoXYNVk6QTZ{N{K=
CTLL2 NHPsOGFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NX22SGlvhjVizszN MV\EUXNQ NGXWc4tKSzVyPkGuNFAh|ryP NX3NeY1OOTl7OU[yO|I>
HTB-47 MnPLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoruglUh|ryP NX\mNYVxTE2VTx?= NGX1OXlKSzVyPUKuNFU3KM7:TR?= NYnYWo5IOTl7OU[yO|I>
LAN-1 NVTCSo83T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUjwUItEhjVizszN NXW1WmdnTE2VTx?= NIPnV2ZKSzVyPUCuNFQh|ryP NYi2XItyOTl7OU[yO|I>
ST486 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHr3N3Z,PSEQvF2= MoK0SG1UVw>? NGS0NnJKSzVyPUGuNVkh|ryP NUnUPYdCOTl7OU[yO|I>
HS766T NYq0TFlWT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXnJW2RChjVizszN MWPEUXNQ NHLoepNKSzVyPUKuNFAyKM7:TR?= NVfVUodoOTl7OU[yO|I>
IMR-32 NGrY[2JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NX;ibWhqhjVizszN NH\H[FdFVVOR MluxTWM2OD1yLkK2NUDPxE1? Mo\qNVk6QTZ{N{K=
Daudi (Burkitt's) M{LGTWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4fiOp42KM7:TR?= MnnCSG1UVw>? MUXJR|UxRTJwNkO3JO69VQ>? Mnf2NVk6QTZ{N{K=
Aspc-1 M1m2Tmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2fNZ542KM7:TR?= NFy2N5NFVVOR NIThZ2pKSzVyPUCuN|c6KM7:TR?= Ml3jNVk6QTZ{N{K=
SK-NSH NVT2VZNuT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUTvOGZNhjVizszN NHjhXWpFVVOR M1HtT2lEPTB;MD6xN|kh|ryP NHfufYUyQTl7NkK3Ni=>
MEC-1 (Chronic B cell) MmHYS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIf6Wm9,PSEQvF2= NXfjTnc3TE2VTx?= MnHsTWM2OD1{Lk[zO{DPxE1? M375O|E6QTl4Mkey
Capan-2 MlzXS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4m2SJ42KM7:TR?= MWDEUXNQ NIizSGNKSzVyPUGuO|c1KM7:TR?= MWWxPVk6PjJ5Mh?=
SHSY5Y NIe5S5dIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmfkglUh|ryP NWjMPXhkTE2VTx?= NWHvXlVYUUN3ME2wMlExPiEQvF2= NHSyZY4yQTl7NkK3Ni=>
U937 (Histioocytic) MonVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHKy[HF,PSEQvF2= NVf5S3h5TE2VTx?= MmDLTWM2OD53LkCwJO69VQ>? NH3jboYyQTl7NkK3Ni=>
Bxpc-1 NEfQT3RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoTNglUh|ryP NY\FSJQzTE2VTx?= MnewTWM2OD1zLkmyOEDPxE1? NXX3cFB7OTl7OU[yO|I>
Bxpc-3 NF7COmtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mki4glUh|ryP NXjLfFI3TE2VTx?= MoG3TWM2OD53LkCwJO69VQ>? MmTSNVk6QTZ{N{K=
HTB-92 NHHk[2xIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4DU[542KM7:TR?= MVrEUXNQ NH7pXJlKSzVyPUGuNFIh|ryP NFrWSnUyQTl7NkK3Ni=>
OCI-LY10 (B-cell) NE\1WnRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXz+OUDPxE1? NHPqdo1FVVOR M13ke2lEPTB;MD60OUDPxE1? MXixPVk6PjJ5Mh?=
PANC-1 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYnSXmJMhjVizszN MULEUXNQ M3XwRmlEPTB-NT6wNEDPxE1? M2SzS|E6QTl4Mkey
To184.T MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUD+OUDPxE1? NVvUXHhSTE2VTx?= M1;Nc2lEPTB;MD60Olkh|ryP MnvENVk6QTZ{N{K=
OCI-LY19 (B-cell) M2XvfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1nNTZ42KM7:TR?= NFfTW49FVVOR NV3MWVQ2UUN3ME2wMlQh|ryP MWCxPVk6PjJ5Mh?=
PANC-1 BM M4T3SWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Ml3sglUh|ryP MmT4SG1UVw>? NEnvWpJKSzVyPkWuNFAh|ryP NFW5elYyQTl7NkK3Ni=>
SA-4 MXzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M3fIOZ42KM7:TR?= MoPQSG1UVw>? NYn3V2dmUUN3ME2xMlMxOSEQvF2= MmDRNVk6QTZ{N{K=
RPMI 8226 MoHRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1rKfJ42KM7:TR?= MlPYSG1UVw>? M1Xzc2lEPTB;MT6yPVMh|ryP MkjINVk6QTZ{N{K=
HPAF-II MoS0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NIHTd5N,PSEQvF2= MUTEUXNQ NFLDNm5KSzVyPUCuOlQ1KM7:TR?= M4DldVE6QTl4Mkey
SHP-77 NVqweHJ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NILHeJd,PSEQvF2= NIHo[ZVFVVOR M1LHPGlEPTB;MT64PFgh|ryP NY\kOGZbOTl7OU[yO|I>
U266 B1 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFHLdnN,PSEQvF2= M4nwUGROW09? MX7JR|UxRTFwNk[5JO69VQ>? M1TnWlE6QTl4Mkey
Hs700t M3\2T2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mlv5glUh|ryP MVLEUXNQ NIPZT2pKSzVyPUCuNlMyKM7:TR?= NHTT[pQyQTl7NkK3Ni=>
NCI-446 NIPHfndIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUHabpZMhjVizszN NH7DW45FVVOR NWLqT4RKUUN3ME2xMlE2PCEQvF2= MlT0NVk6QTZ{N{K=
H929 NWfzeYd3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1ywe542KM7:TR?= MYDEUXNQ MoHDTWM2OD1yLkCxOEDPxE1? NVrEZXI{OTl7OU[yO|I>
PL45 NY\hWWRNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NUfRV5dOhjVizszN NH;QTG5FVVOR MWXJR|UxRTJwMkW1JO69VQ>? MnnKNVk6QTZ{N{K=
NCI-H383 MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NF\PXpV,PSEQvF2= M2\QN2ROW09? NWPSe4E4UUN3ME61MlAxKM7:TR?= NWnBO4lsOTl7OU[yO|I>
JJN3 M3rzVWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYP+OUDPxE1? MUnEUXNQ NY\HSVl6UUN3ME2yMlQ{OyEQvF2= MXuxPVk6PjJ5Mh?=
SU.86.86 M3PJWGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVWxV4NihjVizszN NWjPVWxvTE2VTx?= MVLJR|UxRTJwNkeyJO69VQ>? MWmxPVk6PjJ5Mh?=
H1299 M{XRXGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3XzVJ42KM7:TR?= M2L5RmROW09? Mne3TWM2OD53LkCwJO69VQ>? MlPONVk6QTZ{N{K=
MDA-MB-468 M4C5Umdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NH\uWXZ,PSEQvF2= M1H3RWROW09? M4DDWmlEPTB;MD61NFQh|ryP NVH2ZmNyOTl7OU[yO|I>
SW1990 MmS0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M37pdZ42KM7:TR?= NEnxT4NFVVOR NV3jblcyUUN3ME2wMlgzPiEQvF2= M2SxclE6QTl4Mkey
Calu-6 M3XCVmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MW\+OUDPxE1? NUT1NldvTE2VTx?= MWPJR|UxRjVwMECg{txO M{\aV|E6QTl4Mkey
MDA-MB-231 MlP4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHmyXlJ,PSEQvF2= MUPEUXNQ MUDJR|UxRTFwNkS4JO69VQ>? MlX2NVk6QTZ{N{K=
SW-684 M1f2dGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFH6eGt,PSEQvF2= NGjLNoJFVVOR M4fXR2lEPTB-NT6wNEDPxE1? NUH3fY9UOTl7OU[yO|I>
H209 Mk\ES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4rPPJ42KM7:TR?= M{\4[mROW09? M17QOGlEPTB;MT6xPVMh|ryP MVWxPVk6PjJ5Mh?=
MDA-MB-231T M17YSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVf+OUDPxE1? M4fJbWROW09? M3XEOWlEPTB-NT6wNEDPxE1? M1GyZVE6QTl4Mkey
HT1080/S NFrZcYhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVL+OUDPxE1? Mnf5SG1UVw>? MYXJR|UxRTBwNUOxJO69VQ>? MV[xPVk6PjJ5Mh?=
H526 0.044 M3;wZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmrCglUh|ryP NFPCOHhFVVOR NWjKTldlUUN3ME2wMlA1PCEQvF2= MV[xPVk6PjJ5Mh?=
DU4475 2.431 NETrdFdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmfhglUh|ryP M4TCOWROW09? MmTlTWM2OD1{LkSzNUDPxE1? M2jXTVE6QTl4Mkey
HCT116 M1\lOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mmf2glUh|ryP MoHVSG1UVw>? NYHiRYZvUUN3ME2wMlg2OiEQvF2= NUnxfIpTOTl7OU[yO|I>
M109 NVu0V|JVT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWX+OUDPxE1? NFfQc4RFVVOR NE[xPGdKSzVyPUGuNFU2KM7:TR?= MnnlNVk6QTZ{N{K=
BT549 NUD2c2pbT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWDJb2ZZhjVizszN MUPEUXNQ MUXJR|UxRTFwNkS1JO69VQ>? NHTlXVQyQTl7NkK3Ni=>
HCT116/VM46 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NELFdVJ,PSEQvF2= NX;RXnh{TE2VTx?= M33vWWlEPTB;MT63NFIh|ryP NFrNOpoyQTl7NkK3Ni=>
H460 MWjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUH+OUDPxE1? M1vHWmROW09? M{TCVmlEPTB;MD63PVUh|ryP NVP1UG9YOTl7OU[yO|I>
MCF-7 NELqNFVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4TwRp42KM7:TR?= M1jnVGROW09? NGDWRlVKSzVyPUCuNFE3KM7:TR?= MXKxPVk6PjJ5Mh?=
GEO NWHoSm82T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MX3+OUDPxE1? NVHSRYVKTE2VTx?= MYHJR|UxRTBwM{W2JO69VQ>? M4\ld|E6QTl4Mkey
H441 0.646 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGOxZ45,PSEQvF2= MmrrSG1UVw>? Mn[yTWM2OD1yLk[0OkDPxE1? MWqxPVk6PjJ5Mh?=
MCF-7-807R MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2T3eZ42KM7:TR?= MmfNSG1UVw>? NWDEZ4JTUUN3ME2wMlQ6KM7:TR?= NGDWfYcyQTl7NkK3Ni=>
Colo205 MkLMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NX3wUYpWhjVizszN MoPCSG1UVw>? NUTrUmw2UUN3ME2wMlExPCEQvF2= NY[xZokyOTl7OU[yO|I>
H292 MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MUT+OUDPxE1? NF;qT4ZFVVOR MmXMTWM2OD1yLke4PEDPxE1? NHXQbJMyQTl7NkK3Ni=>
BT474 (S) MmTmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUT5SmpEhjVizszN NWPEdldMTE2VTx?= M{HrdmlEPTB;Mj60NFMh|ryP MYKxPVk6PjJ5Mh?=
HT-29 MlrOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWn+OUDPxE1? MlT5SG1UVw>? NGS1SW1KSzVyPUKuNVA{KM7:TR?= NIfYR2gyQTl7NkK3Ni=>
A549 NH31TI5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHvmZ2R,PSEQvF2= M4HoTmROW09? NV;kNmFUUUN3ME2wMlY4PSEQvF2= Ml\CNVk6QTZ{N{K=
BT474-M1 MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2Hz[542KM7:TR?= NGHxOG1FVVOR MnXlTWM2OD1{LkO2OUDPxE1? NEP1dXgyQTl7NkK3Ni=>
SW480 M1jZbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVvSRmJyhjVizszN MlPrSG1UVw>? M2f3c2lEPTB-NT6wNEDPxE1? M{ToU|E6QTl4Mkey
L2987 M{nIUmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1;vRZ42KM7:TR?= NFmzZ25FVVOR Mo[3TWM2OD1yLkS0NkDPxE1? MVGxPVk6PjJ5Mh?=
AU565 MnruS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXLRfJlUhjVizszN M37PTGROW09? NX[zfpRoUUN3ME20Mlk4KM7:TR?= MVexPVk6PjJ5Mh?=
SW403 NX30c3NvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGPoXHR,PSEQvF2= NH[5d4pFVVOR NFHYdFdKSzVyPUCuNlIh|ryP NHvJRWUyQTl7NkK3Ni=>
H1437 M2DpWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MUP+OUDPxE1? NXXqTGxRTE2VTx?= MVfJR|UxRTBwNUKzJO69VQ>? NVn0TJpMOTl7OU[yO|I>
BT-20 MkTuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWD+OUDPxE1? NH\ObVNFVVOR Ml;aTWM2OD1|LkW2NkDPxE1? NHftWoUyQTl7NkK3Ni=>
Colo320HSR MojiS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1XRfJ42KM7:TR?= M3nuOWROW09? NEfPWpVKSzVyPUCuNFEyKM7:TR?= NH7wTWsyQTl7NkK3Ni=>
H2087 MmHhS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{fEc542KM7:TR?= MUjEUXNQ MWrJR|UxRjFwMECg{txO NH;sc3YyQTl7NkK3Ni=>
HCC1419 NFTTNYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mm\1glUh|ryP NWrnbI9iTE2VTx?= M1HZOmlEPTB;Mj61NVch|ryP NFfhO2QyQTl7NkK3Ni=>
WiDr NG\tSXpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M360bp42KM7:TR?= NVWyb3plTE2VTx?= M{jzTWlEPTB;MD6wO|Yh|ryP NVKyT2NXOTl7OU[yO|I>
H661 0.573 NVHpV|F[T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NH;SSmJ,PSEQvF2= NF3wVY9FVVOR M3PDV2lEPTB;MD61O|Mh|ryP M2WwS|E6QTl4Mkey
HCC-38 NEj0clJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH32Uol,PSEQvF2= MmjFSG1UVw>? MV;JR|UxRjVwMECg{txO NV\KZWtFOTl7OU[yO|I>
LS174T MlTUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmqxglUh|ryP M4LWUWROW09? NUnVZYg3UUN3ME2wMlU{PSEQvF2= MXqxPVk6PjJ5Mh?=
H211 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NInRbHJ,PSEQvF2= NWLKRW5oTE2VTx?= NYHtb2RFUUN3ME2wMlc{OyEQvF2= MY[xPVk6PjJ5Mh?=
HCC70 MmnRS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXrRT2luhjVizszN NEXKRXJFVVOR MUXJR|UxRTFwNUWg{txO MXmxPVk6PjJ5Mh?=
SW116 M1Gzb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NInCN4Z,PSEQvF2= NUi4UG9TTE2VTx?= NFfUSo9KSzVyPUCuNFY4KM7:TR?= MWKxPVk6PjJ5Mh?=
H513 M{nId2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1m2bJ42KM7:TR?= MnXaSG1UVw>? MXrJR|UxRTRwNES4JO69VQ>? NXzNcVJ3OTl7OU[yO|I>
MDA-MB-157 MYTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXnLdZp{hjVizszN MmfrSG1UVw>? MX3JR|UxRTBwMEO2JO69VQ>? Mn\MNVk6QTZ{N{K=
H2052 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHzrbld,PSEQvF2= M4HwOWROW09? Mn\QTWM2OD1zLkC1JO69VQ>? NEi2WVUyQTl7NkK3Ni=>
MDA-MB-415 NF;ORlFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWP5em0zhjVizszN NFT0c3lFVVOR MV\JR|UxRjVwMECg{txO MnvnNVk6QTZ{N{K=
DLD-1 MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MlmyglUh|ryP MlLGSG1UVw>? NX;icZlMUUN3ME2wMlkxQSEQvF2= NInv[3YyQTl7NkK3Ni=>
H2595 NGfzOopIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MmDYglUh|ryP NI\1UnFFVVOR MYfJR|UxRTRwNEe1JO69VQ>? M2CwSFE6QTl4Mkey
MDA-MB-435S MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVf2XHJXhjVizszN MnjXSG1UVw>? MVvJR|UxRTFwOE[5JO69VQ>? MVKxPVk6PjJ5Mh?=
HCT15 MmPwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVrz[lByhjVizszN MVPEUXNQ MVfJR|UxRjFwMECg{txO MVuxPVk6PjJ5Mh?=
SK-Hep1 NVPHSGpMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFHlOId,PSEQvF2= M1TUV2ROW09? MWTJR|UxRTBwMUS2JO69VQ>? M4XDXVE6QTl4Mkey
MDA-MB-436 MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmrpglUh|ryP MoHZSG1UVw>? Ml3QTWM2OD13LkWwNkDPxE1? MV6xPVk6PjJ5Mh?=
KM12C MljWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYPkO41MhjVizszN MnjtSG1UVw>? M3Tmd2lEPTB;MD6wOVQh|ryP MoLpNVk6QTZ{N{K=
HEPG2 MXrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXf+OUDPxE1? NE\pO3JFVVOR MXLJR|UxRTBwMEK1JO69VQ>? NUHFdlJmOTl7OU[yO|I>
MDA-MB-453 NVy0bm1xT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MYr+OUDPxE1? MWTEUXNQ M2K1VmlEPTB;MT64Olkh|ryP M{frZlE6QTl4Mkey
KM12SM MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NV;VXZQ5hjVizszN MlrDSG1UVw>? NUTkc3NKUUN3ME2wMlA2QSEQvF2= MVqxPVk6PjJ5Mh?=
1483 MnTzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M3LCfp42KM7:TR?= NEDtUVNFVVOR NEW5UZJKSzVyPUKuNVkh|ryP MlW0NVk6QTZ{N{K=
Hs578t NH7iToNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVXMT5pUhjVizszN NGi2SVNFVVOR M1LUc2lEPTB;MT6yPFch|ryP NIHZSGgyQTl7NkK3Ni=>
LS180 M1KxVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mmr4glUh|ryP Ml;uSG1UVw>? NXTQXpBKUUN3ME2wMlY6PiEQvF2= NHzzWFQyQTl7NkK3Ni=>
FaDu NWPhZ4ZnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MkPHglUh|ryP NYT4bpRbTE2VTx?= Mm\GTWM2OD1zLkK3JO69VQ>? M3nt[FE6QTl4Mkey
ZR-75-1 MnfmS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHjJbWN,PSEQvF2= MnHaSG1UVw>? M3\tcGlEPTB;Mj6wPFQh|ryP MnzTNVk6QTZ{N{K=
LS513 NVvHPGVTT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NIO3VVV,PSEQvF2= MoHJSG1UVw>? MVrJR|UxRTBwMUO1JO69VQ>? NHvOZZQyQTl7NkK3Ni=>
Detroit.562 M4rZNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3\QWZ42KM7:TR?= MVHEUXNQ NV7kU3JHUUN3ME2xMlE1KM7:TR?= NFzTOlgyQTl7NkK3Ni=>
ZR-75-30 M3LiZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NVnIXXU6hjVizszN NHTVOY1FVVOR MlXBTWM2OD53LkCwJO69VQ>? MWGxPVk6PjJ5Mh?=
RKO-PM MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NEXKfGZ,PSEQvF2= NVr1XXBsTE2VTx?= M3vRXmlEPTB;MD6yN|Ih|ryP NF7NNWcyQTl7NkK3Ni=>
Cal.27 MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M2D6TJ42KM7:TR?= MY\EUXNQ M1zDSWlEPTB;MjFOwG0> NHrwU3gyQTl7NkK3Ni=>
KPL4 M{OxO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWq3TGRohjVizszN Ml\XSG1UVw>? MkLDTWM2OD1zLkK1NkDPxE1? M3PTZVE6QTl4Mkey
PKO-RM13 Ml3wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUi4RWUyhjVizszN NIXSO5VFVVOR Mn;mTWM2OD1yLkSyOUDPxE1? MVqxPVk6PjJ5Mh?=
HS.53.T MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGfsNlZ,PSEQvF2= MXnEUXNQ NXLRT4syUUN3ME2wMlc6KM7:TR?= NYDLdnI1OTl7OU[yO|I>
EMT6 Ml3IS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MoTuglUh|ryP MkHOSG1UVw>? NHLJZoVKSzVyPUCuPFA3KM7:TR?= NFfNWFkyQTl7NkK3Ni=>
SNU-C1 MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MX7+OUDPxE1? M{jyeGROW09? NEL2dJJKSzVyPUCuNFA4KM7:TR?= M3nUWlE6QTl4Mkey
SQCCY1 MorxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MVv+OUDPxE1? MoHRSG1UVw>? NY[4bJA{UUN3ME2wMlc6KM7:TR?= Mk\0NVk6QTZ{N{K=
SW480 M1\UUWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MVf+OUDPxE1? M2fhbmROW09? MVzJR|UxRTBwMEO3JO69VQ>? NUPhVWN6OTl7OU[yO|I>
SCC9 Mo\CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NELuNlB,PSEQvF2= MmDsSG1UVw>? NX3OTW1JUUN3ME2wMlc2KM7:TR?= MlnjNVk6QTZ{N{K=
SK-LMS-1 MlfKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHOzW4F,PSEQvF2= NHPHXlZFVVOR M1H0ZWlEPTB;MD62PFch|ryP M4DB[|E6QTl4Mkey
SCC25 MVzHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHv6OIh,PSEQvF2= M4C5NGROW09? NF3WUplKSzVyPUCuOlgh|ryP MWGxPVk6PjJ5Mh?=
U87 MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXLOPHZIhjVizszN MUnEUXNQ MUXJR|UxRTBwOUWg{txO MlvjNVk6QTZ{N{K=
SCC15 MmC3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYTUfZROhjVizszN NGrNdYJFVVOR MkfOTWM2OD1yLk[3JO69VQ>? NXf6foE{OTl7OU[yO|I>
T98G NF;IUVZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIGyUGt,PSEQvF2= NYXUU3F[TE2VTx?= MV\JR|UxRTFwMkG4JO69VQ>? MYWxPVk6PjJ5Mh?=
SCC4 NXjsSpA1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NX\5T4V4hjVizszN M13abGROW09? MkPiTWM2OD1yLk[zJO69VQ>? NFzaSmwyQTl7NkK3Ni=>
U118 MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmG3glUh|ryP NVPwR2dGTE2VTx?= MknMTWM2OD1zLk[xPEDPxE1? NUfDUG0yOTl7OU[yO|I>
TU167 MlHuS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1\PbJ42KM7:TR?= MXTEUXNQ NVfy[5ZtUUN3ME20MlUzKM7:TR?= M4TYcFE6QTl4Mkey
NCI-H727 M4\0emdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3rpUp4yOOLCit88US=> M4nt[GROW09? MoTtTWM2OD12Mkigcm0> M3f6NlIxOzh3N{S3
NCI-H720 NUjzUHBJT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NEDz[5N,OTEkgJtOwG0> NFLpR4dFVVOR NIHifIpKSzVyPUKuPEDPxE1? MVmyNFM5PTd2Nx?=
NCI-H835 M1uwfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXX+NVDjiIsQvF2= M4HZd2ROW09? MWDJR|UxRTFizszN NF\5OXMzODN6NUe0Oy=>
NCI-H727 M4LYR2tqdmG|ZTDhd5NigQ>? MkjaglEx6oDMzszN MkjaSG1UVw>? MXLpcohq[mm2czDjc45{fGm2dYTpeoUhUUeIMWKgZZV1d3Cqb4PwbI9zgWyjdHnvci=> MnnLNlA{QDV5NEe=
RD MmmyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVLPfI1[hjFy4pEK{txO MVjJR|UxRTFwMUKgxtVO Ml7SNlEzQTh5NEW=
Rh41 NWizd|JET3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NG\sU4d,OTEkgJtOwG0> Mne5TWM2OD1yLkC3JOK2VQ>? MWeyNVI6QDd2NR?=
Rh18 M3\VXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFW1N21,OTEkgJtOwG0> M{XKWGlEPTB;ND65OkDDvU1? MnLnNlEzQTh5NEW=
Rh30 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NIXpUYJ,OTEkgJtOwG0> NHj0eXRKSzVyPUCuNVkhyrWP MnXPNlEzQTh5NEW=
BT-12 NH3kVmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVn+NVDjiIsQvF2= NFzBZ4hKSzVyPUCuO|ghyrWP M4XF[|IyOjl6N{S1
CHLA-266 NInRT2JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MVr+NVDjiIsQvF2= MXLJR|UxRTBwOEmgxtVO MmfJNlEzQTh5NEW=
TC-71 NX7WNok1T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MWL+NVDjiIsQvF2= MkPPTWM2OD1yLkGxJOK2VQ>? M1XySFIyOjl6N{S1
CHLA-9 M1PYeWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4ixVJ4yOOLCit88US=> MmDXTWM2OD1yLkGyJOK2VQ>? MmHVNlEzQTh5NEW=
CHLA-10 M1LjSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWHwdWM1hjFy4pEK{txO NGXqe2tKSzVyPUCuOlIhyrWP M4raVlIyOjl6N{S1
CHLA-258 MoTwS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{SwWZ4yOOLCit88US=> MXzJR|UxRTBwMkegxtVO MUGyNVI6QDd2NR?=
GBM2 NVLhe2FOT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MW\+NVDjiIsQvF2= MknrTWM2OD1zLkS3JOK2VQ>? MYWyNVI6QDd2NR?=
NB-1643 Ml\GS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWP+NVDjiIsQvF2= NFvsU2pKSzVyPUCuNVIhyrWP NH\nRpMzOTJ7OEe0OS=>
NB-EBc1 NH[3ZXBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHv5eVh,OTEkgJtOwG0> MX\JR|UxRTBwM{WgxtVO MlzFNlEzQTh5NEW=
CHLA-90 NFvhPJdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHjCT5B,OTEkgJtOwG0> M125XmlEPTB;MD63O{DDvU1? MoHBNlEzQTh5NEW=
CHLA-136 MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mm[1glEx6oDMzszN NV;uU5UxUUN3ME2wMlUzKML3TR?= Mo\NNlEzQTh5NEW=
NALM-6 Mm\NS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWTWT2s2hjFy4pEK{txO M1XTUWlEPTB;MD60PUDDvU1? Ml7lNlEzQTh5NEW=
COG-LL-317 MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NU\wOnpThjFy4pEK{txO MV3JR|UxRTFwM{igxtVO M3nVRlIyOjl6N{S1
RS4;11 M4DZcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4nPep4yOOLCit88US=> MkTBTWM2OD1yLkO4JOK2VQ>? MnHNNlEzQTh5NEW=
MOLT-4 NWXEe3BRT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MUj+NVDjiIsQvF2= NXfqcoNEUUN3ME2wMlU{KML3TR?= MX:yNVI6QDd2NR?=
CCRF-CEM M4nrfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MYL+NVDjiIsQvF2= M2TyW2lEPTB;MT6xN{DDvU1? M4HHclIyOjl6N{S1
Kasumi-1 NV;TcJZpT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVj+NVDjiIsQvF2= NEfWS5JKSzVyPUGuNkDDvU1? M172flIyOjl6N{S1
Karpas-299 NITLOW1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUnSfJlThjFy4pEK{txO Mk\hTWM2OD1zLk[0JOK2VQ>? NWLnSnl3OjF{OUi3OFU>
Ramos-RA1 NI[3ZYZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGXaRld,OTEkgJtOwG0> NVe2eXJ{UUN3ME2xMlMyKML3TR?= MlfaNlEzQTh5NEW=
Rh30  M{XD[GZ2dmO2aX;uJIF{e2G7 M2PYO4lv\HWlZYOgZY4hcW6lcnXhd4Uhd2ZiU1\LJJBpd3OyaH;yfYxifGmxbh?= M{PyUlI2QTJ3M{e4
Rh41 MX;GeY5kfGmxbjDhd5NigQ>? MoPabY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w NIPNeHgzPTl{NUO3PC=>
RD NF3Jd5hHfW6ldHnvckBie3OjeR?= MortbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w NVXsdW0{OjV7MkWzO|g>
A549 MorHT4lv[XOnIHHzd4F6 MnfHNE426oDMzszN MV;EUXNQ NIXyTINqdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>? MX6yOlkzQDV5OB?=
NCI-H358 NVHYZY44U2mwYYPlJIF{e2G7 MnGzNE426oDMzszN MlXnSG1UVw>? MV3pcohq[mm2czDJS2YuUVJxSWKgZYN1cX[jdHnvci=> NVHjR|UyOjZ7Mki1O|g>
A549 M3jrNGZ2dmO2aX;uJIF{e2G7 M3fnd|AvPeLCit88US=> NWn0[4VvTE2VTx?= Mo\UZ4F2e2W|IHGgZ49v[3W{cnXueEBl\WO{ZXHz[UBqdiCyaH;zdIhwenmuYYTl[EBCU1RiYX7kJGVTUw>? MVeyOlkzQDV5OB?=
NCI-H358 M3Plb2Z2dmO2aX;uJIF{e2G7 Mny4NE426oDMzszN MV7EUXNQ NYnacpIy[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?= Mn\GNlY6Ojh3N{i=
A549 NVfORoJnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3nRW54yOOLCit88US=> NWXHT5B[TE2VTx?= Moj1TWM2OD1yLke2JO69VQ>? NYPH[oY3OjZ7Mki1O|g>
NCI-H358 M1TsV2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkTYglEx6oDMzszN MnPmSG1UVw>? MVrJR|UxRTFwMEmg{txO NVnqcVVuOjZ7Mki1O|g>
A549 MljzRZBweHSxc3nzJIF{e2G7 NEH2R4YxNjYkgJtOwG0> M4jaW2ROW09? NVryd3RNcW6mdXPld{BCeG:ydH;zbZM> M{LhelI3QTJ6NUe4
NCI-H358 NYHCNItVSXCxcITvd4l{KGG|c3H5 M1rK[FAvPeLCit88US=> MUnEUXNQ Mn;vbY5lfWOnczDBdI9xfG:|aYO= NVL4R4hxOjZ7Mki1O|g>
A549 M2LsOmZ2dmO2aX;uJIF{e2G7 MX:wMlXjiIsQvF2= NF3KPWlFVVOR NUi5WWdFemWmdXPld{B4d3WwZDDjcI9{fXKn NFfLb3AzPjl{OEW3PC=>
NCI-H358 NXrjV3pVTnWwY4Tpc44h[XO|YYm= NH7SPXIxNjYkgJtOwG0> MnXDSG1UVw>? MkXjdoVlfWOnczD3c5Vv\CClbH;zeZJm NVnsNWhvOjZ7Mki1O|g>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 26136493     


(C) T4105 cells were treated with OSI-906 or BMS-754807 at indicated concentrations for 24 hours, lysed, and subjected to immunoblotting.

26136493
Growth inhibition assay
Cell viability; 

PubMed: 30754629     


Response of SK-CO-1 to various drugs and drug combinations.

30754629
体内試験 BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

Kinase inhibition assays:

The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
細胞試験: [1]
- 合併
  • 細胞株: IGF-1R-Sal, RH41 and Geo cell lines
  • 濃度: 365 nM
  • 反応時間: 72 hours
  • 実験の流れ: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells.
    (参考用のみ)
動物試験:[1]
- 合併
  • 動物モデル: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice
  • 投薬量: 150 mg/kg
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 92 mg/mL (199.35 mM)
Ethanol 92 mg/mL (199.35 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 461.49
化学式

C23H24FN9O

CAS No. 1001350-96-4
Storage powder
in solvent
別名 N/A
Smiles CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

IGF-1Rシグナル伝達経路

IGF-1R Inhibitors with Unique Features

相関IGF-1R製品

Tags: BMS-754807を買う | BMS-754807 ic50 | BMS-754807供給者 | BMS-754807を購入する | BMS-754807費用 | BMS-754807生産者 | オーダーBMS-754807 | BMS-754807化学構造 | BMS-754807分子量 | BMS-754807代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID